Ryan Spencer - Dynavax Technologies President
| DVAX Stock | USD 13.01 0.03 0.23% |
President
Mr. Ryan Spencer is Interim CoPresident, CoPrincipal Executive Officer of the Company. Mr. Spencer joined Dynavax in November, 2006, as Associate Director, External Reporting. Since then, he held a variety of positions with increasing responsibility, leading to his current role as Senior Vice President, Commercial. Prior to joining Dynavax, Mr. Spencer was the Assistant Controller at QRS Corporationrationration, a publiclyheld technology company, and was a member of the audit practice at Ernst Young since 2019.
| Age | 47 |
| Tenure | 6 years |
| Address | 2100 Powell Street, EmeryVille, CA, United States, 94608 |
| Phone | 510 848 5100 |
| Web | https://www.dynavax.com |
Ryan Spencer Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ryan Spencer against Dynavax Technologies stock is an integral part of due diligence when investing in Dynavax Technologies. Ryan Spencer insider activity provides valuable insight into whether Dynavax Technologies is net buyers or sellers over its current business cycle. Note, Dynavax Technologies insiders must abide by specific rules, including filing SEC forms every time they buy or sell Dynavax Technologies'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ryan Spencer over six months ago Acquisition by Ryan Spencer of 402 shares of Dynavax Technologies subject to Rule 16b-3 | ||
Ryan Spencer over six months ago Exercise or conversion by Ryan Spencer of 20833 shares of Dynavax Technologies subject to Rule 16b-3 | ||
Ryan Spencer over six months ago Exercise or conversion by Ryan Spencer of 29750 shares of Dynavax Technologies subject to Rule 16b-3 | ||
Ryan Spencer over a year ago Acquisition by Ryan Spencer of 1668 shares of Dynavax Technologies subject to Rule 16b-3 |
Dynavax Technologies Management Efficiency
Return On Tangible Assets is likely to drop to -0.0061 in 2025. Return On Capital Employed is likely to drop to -0.04 in 2025. At this time, Dynavax Technologies' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 166.6 M in 2025, whereas Other Assets are likely to drop slightly above 3 M in 2025. Dynavax Technologies' management efficiency ratios could be used to measure how well Dynavax Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Carol Walker | Lantheus Holdings | 61 | |
| Scott Dreyer | Collegium Pharmaceutical | 53 | |
| Robert Davis | Intracellular Th | 74 | |
| Shirley Kuhlmann | Collegium Pharmaceutical | 40 | |
| Richard Lindahl | Emergent Biosolutions | 60 | |
| Daniel Barber | Aquestive Therapeutics | 49 | |
| Sean Kirk | Emergent Biosolutions | 45 | |
| Juan Sanchez | Intracellular Th | 53 | |
| Peter Boyd | Aquestive Therapeutics | 59 | |
| Katherine Strei | Emergent Biosolutions | 62 | |
| Michael Landine | Alkermes Plc | 70 | |
| David Gaffin | Alkermes Plc | 52 | |
| Etienne Montagut | Lantheus Holdings | 49 | |
| John Condon | Intracellular Th | N/A | |
| Mark Neumann | Intracellular Th | 62 | |
| Robert Kramer | Emergent Biosolutions | 62 | |
| Stephen Carey | ANI Pharmaceuticals | 54 | |
| Joseph Ciaffoni | Collegium Pharmaceutical | 53 | |
| Adam Havey | Emergent Biosolutions | 53 | |
| John Bardi | Intracellular Th | N/A | |
| Atul Saran | Emergent Biosolutions | 51 | |
Management Performance
| Return On Equity | 0.0318 | ||||
| Return On Asset | -0.0038 |
Dynavax Technologies Leadership Team
Elected by the shareholders, the Dynavax Technologies' board of directors comprises two types of representatives: Dynavax Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dynavax. The board's role is to monitor Dynavax Technologies' management team and ensure that shareholders' interests are well served. Dynavax Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dynavax Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Riccardo Manetti, Business President | ||
| Eric Frings, Site VP | ||
| Robert Janssen, Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs | ||
| David Novack, Sr. VP of Operations and Quality | ||
| Robert MD, Medical Development | ||
| Donn Casale, Senior Officer | ||
| Nicole Arndt, Sr Relations | ||
| Kelly MacDonald, Senior CFO | ||
| Paul Cox, VP Communications | ||
| Dong Yu, Senior Research | ||
| Ryan Spencer, Interim Co-President Co-Principal Executive Officer | ||
| John Slebir, Senior Counsel | ||
| Jeff Coon, CHRO Administration | ||
| Kelly CPA, Senior CFO | ||
| Justin Burgess, Principal Controller | ||
| Michael Ostrach, Principal Financial Officer, Vice President General Counsel, Chief Business Officer | ||
| Meg Smith, VP Operations | ||
| Todd Lopeman, Senior Operations |
Dynavax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dynavax Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0318 | ||||
| Return On Asset | -0.0038 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 1.19 B | ||||
| Shares Outstanding | 131.46 M | ||||
| Shares Owned By Insiders | 0.33 % | ||||
| Shares Owned By Institutions | 99.67 % | ||||
| Number Of Shares Shorted | 19.17 M | ||||
| Price To Earning | 6.95 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Dynavax Stock Analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.